Sonochemical route for self-assembled V2O5 bundles with spindle-like morphology and their novel application in serum albumin sensing

Novel self-assembled V2O5 bundles with highly ordered superstructures and spindle-like morphology were synthesized by a rapid high-yielding sonochemical method. The as-prepared samples were characterized by X-ray diffraction, a field-emission scanning electron microscope, and a transmission electron microscope. The spindle-like V2O5 bundles are composed of several tens of homogeneous nanowires with diameters of 30-50 nm and lengths of 3-7 microm. A sensitive resonance light scattering method for the detection of bovine serum albumin (BSA) based on the self-assembled V2O5 bundles was developed. The results of the polarized resonance light scattering demonstrated that the Cabannes factor for the V2O5 bundles-BSA aggregates was BSA concentration-dependent.     

Preparation of branched structures with long DNA duplex arms

Branched structures with long DNA duplex arms have been constructed through biotin-streptavidin binding and characterized by gel electrophoresis and atomic force microscopy (AFM) imaging.     

QSAR modeling of in vitro inhibition of cytochrome P450 3A4

We report the QSAR modeling of cytochrome P450 3A4 (CYP3A4) enzyme inhibition using four large data sets of in vitro data. These data sets consist of marketed drugs and drug-like compounds all tested in four assays measuring the inhibition of the metabolism of four different substrates by the CYP3A4 enzyme. The four probe substrates are benzyloxycoumarin, testosterone, benzyloxyresorufin, and midazolam. We first show that using state-of-the-art QSAR modeling approaches applied to only one of these four data sets does not lead to predictive models that would be useful for in silico filtering of chemical libraries. We then present the development and the testing of a multiple pharmacophore hypothesis (MPH) that is formulated as a conceptual extension of the traditional QSAR approach to modeling the promiscuous binding of a large variety of drugs to CYP3A4. In the simplest form, the MPH approach takes advantage of the multiple substrate data sets and identifies the binding of test compounds as either proximal or distal relative to that of a given substrate. Application of the approach to the in silico filtering of test compounds for potential inhibitors of CYP3A4 is also presented. In addition to an improvement in the QSAR modeling for the inhibition of CYP3A4, the results from this modeling approach provide structural insights into the drug-enzyme interactions. The existence of multiple inhibition data sets in the BioPrint database motivates the original development of the concept of a multiple pharmacophore hypothesis and provides a unique opportunity for formulating alternative strategies of QSAR modeling of the inhibition of the in vitro metabolism of CYP3A4.     

Origin of the single chain magnet behavior of the Co(H2L)(H2O) compound with a 1D structure

The paper is aimed at the elucidation of the main factors responsible for the single-chain magnet behavior of the cobalt(II) disphosphonate compound Co(H2L)(H2O) with a 1D structure. The model takes into account the spin-orbit interaction, the axial component of the octahedral crystal field acting on the ground-state cubic 4T1 terms of the Co(II) ions, the antiferromagnetic exchange interaction between Co(II) ions as well as the difference in the crystallographic positions of these ions. The conditions that favor the single-chain magnet behavior based on spin canting in a 1D chain containing inequivalent Co(II) centers are discussed. The peculiarities of this behavior in chains containing orbitally degenerate ions are revealed. The qualitative explanation of the experimental data is given.     

带时变时滞的不确定离散奇异系统鲁棒稳定性分析

为了降低不确定离散奇异时变时滞系统稳定性条件的保守性,首先,采用时滞分割方法,获得了新的时滞系统描述方法,并通过综合考虑各时滞分割子区间,提出了分割子区间依赖型Lyapunov函数.其次,采用时滞依赖线性矩阵不等式技术,将研究结果描述成易于求解的严格线性矩阵不等式形式.通过Matlab工具箱求解线性矩阵不等式,即可获得标称系统正则、因果及均方稳定的条件,并将标称系统的研究结果推广至不确定离散奇异时变时滞系统的稳定性分析,获得了不确定离散奇异时变时滞系统鲁棒稳定判定条件.最后通过实例应用说明了所提定理的有效性,且与现有文献结果相比,保守性得到了较大程度的降低.     

ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner

R-spondin proteins strongly potentiate Wnt signalling and function as stem-cell growth factors. Despite the biological and therapeutic significance, the molecular mechanism of R-spondin action remains unclear. Here we show that the cell-surface transmembrane E3 ubiquitin ligase zinc and ring finger 3 (ZNRF3) and its homologue ring finger 43 (RNF43) are negative feedback regulators of Wnt signalling. ZNRF3 is associated with the Wnt receptor complex, and inhibits Wnt signalling by promoting the turnover of frizzled and LRP6. Inhibition of ZNRF3 enhances Wnt/β-catenin signalling and disrupts Wnt/planar cell polarity signalling in vivo. Notably, R-spondin mimics ZNRF3 inhibition by increasing the membrane level of Wnt receptors. Mechanistically, R-spondin interacts with the extracellular domain of ZNRF3 and induces the association between ZNRF3 and LGR4, which results in membrane clearance of ZNRF3. These data suggest that R-spondin enhances Wnt signalling by inhibiting ZNRF3. Our study provides new mechanistic insights into the regulation of Wnt receptor turnover, and reveals ZNRF3 as a tractable target for therapeutic exploration.     

Re-emerging superconductivity at 48 kelvin in iron chalcogenides

Pressure has an essential role in the production and control of superconductivity in iron-based superconductors. Substitution of a large cation by a smaller rare-earth ion to simulate the pressure effect has raised the superconducting transition temperature T(c) to a record high of 55?K in these materials. In the same way as T(c) exhibits a bell-shaped curve of dependence on chemical doping, pressure-tuned T(c) typically drops monotonically after passing the optimal pressure. Here we report that in the superconducting iron chalcogenides, a second superconducting phase suddenly re-emerges above 11.5?GPa, after the T(c) drops from the first maximum of 32?K at 1?GPa. The T(c) of the re-emerging superconducting phase is considerably higher than the first maximum, reaching 48.0-48.7?K for Tl(0.6)Rb(0.4)Fe(1.67)Se(2), K(0.8)Fe(1.7)Se(2) and K(0.8)Fe(1.78)Se(2).     

中国剩余定理及其应用——基于研究性学习的设计

中国剩余定理在数论及代数理论的研究中起着重要的作用,是一个极其重要的定理.通过中国剩余定理的历史起源来给出该定理及其证明方法,在此基础上对该定理的应用进行了讨论和分析,并给出了一些例子.     

基于分形布朗业务模型的差分队列服务建模

差分队列服务(DQS)是一种在有线与无线融合网络中能有效提供服务质量的服务质量模型,文中基于DQS的思想,将具有相同时延要求的到达业务作为一个分形布朗运动(FBM)业务,建立了一个针对多个FBM业务及对应时延要求的差分队列服务模型,并推导出该模型下的丢包率公式.仿真结果表明,文中模型分析的结果与基于数据包粒度的仿真结果是一致的.模型性能分析结果表明,实时业务的突发性对差分队列服务的服务质量保证影响较大.     

Preparation and cellular uptake of PLGA particles loaded with lamivudine

Poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles loaded with lamivudine and coated with bovine serum albumin (BSA) were prepared via a double emulsion method. The influences of experiments parameters such as volume of inner aqueous phase, concentration of organic phase and ultrasonication time on the particle size and drug entrapment efficiency were investigated, obtaining PLGA particles with a diameter of ~260 nm and drug entrapment efficiency of ~35%. The particles were observed by scanning electron microscopy and transmittance electron microscopy, showing a core-shell structure. BCA assay found that 58 mg BSA was present on/in 1 g LPB particles. The loaded lamivudine showed a burst release at beginning and sustained release until 24 h in physiological conditions. Low pH could accelerate the release of lamivudine from PLGA particles, making the PLGA particles potential intelligent intracellular drug carriers. The PLGA particles were readily internalized into the human liver cells within a short time and increased gradually with the prolongation of incubation time regardless of the loading of lamivudine. The particles either resided within lysosomes or transferred to cytoplasm, but could not enter into the cell nucleus. The cell viability was not significantly influenced in the presence of the particles regardless of lamivudine encapsulation, suggesting that this kind of particles may be a good candidate for the intracellular anti-hepatitis B drug delivery.